TY - JOUR
T1 - Associations of regular glucosamine use with all-cause and cause-specific mortality
T2 - A large prospective cohort study
AU - Li, Zhi Hao
AU - Gao, Xiang
AU - Chung, Vincent C.H.
AU - Zhong, Wen Fang
AU - Fu, Qi
AU - Lv, Yue Bin
AU - Wang, Zheng He
AU - Shen, Dong
AU - Zhang, Xi Ru
AU - Zhang, Pei Dong
AU - Li, Fu Rong
AU - Huang, Qing Mei
AU - Chen, Qing
AU - Song, Wei Qi
AU - Wu, Xian Bo
AU - Shi, Xiao Ming
AU - Kraus, Virginia Byers
AU - Yang, Xingfen
AU - Mao, Chen
N1 - Funding Information:
Funding This work was supported by the national natural science Foundation of china (81973109), the project supported by guangdong province Universities and colleges pearl River scholar Funded scheme (2019), the national Key Research and development program of china (2018YFc2000400), the construction of High-level University of guangdong (g619339521 and g618339167) and the national institutes of Health (niH)/national institute on ageing (nia) of Usa (p30-ag028716).
Publisher Copyright:
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.
PY - 2020/6/1
Y1 - 2020/6/1
N2 - Objectives To evaluate the associations of regular glucosamine use with all-cause and cause-specific mortality in a large prospective cohort. Methods This population-based prospective cohort study included 495 077 women and men (mean (SD) age, 56.6 (8.1) years) from the UK Biobank study. Participants were recruited from 2006 to 2010 and were followed up through 2018. We evaluated all-cause mortality and mortality due to cardiovascular disease (CVD), cancer, respiratory and digestive disease. HRs and 95% CIs for all-cause and cause-specific mortality were calculated using Cox proportional hazards models with adjustment for potential confounding variables. Results At baseline, 19.1% of the participants reported regular use of glucosamine supplements. During a median follow-up of 8.9 years (IQR 8.3-9.7 years), 19 882 all-cause deaths were recorded, including 3802 CVD deaths, 8090 cancer deaths, 3380 respiratory disease deaths and 1061 digestive disease deaths. In multivariable adjusted analyses, the HRs associated with glucosamine use were 0.85 (95% CI 0.82 to 0.89) for all-cause mortality, 0.82 (95% CI 0.74 to 0.90) for CVD mortality, 0.94 (95% CI 0.88 to 0.99) for cancer mortality, 0.73 (95% CI 0.66 to 0.81) for respiratory mortality and 0.74 (95% CI 0.62 to 0.90) for digestive mortality. The inverse associations of glucosamine use with all-cause mortality seemed to be somewhat stronger among current than non-current smokers (p for interaction=0.00080). Conclusions Regular glucosamine supplementation was associated with lower mortality due to all causes, cancer, CVD, respiratory and digestive diseases.
AB - Objectives To evaluate the associations of regular glucosamine use with all-cause and cause-specific mortality in a large prospective cohort. Methods This population-based prospective cohort study included 495 077 women and men (mean (SD) age, 56.6 (8.1) years) from the UK Biobank study. Participants were recruited from 2006 to 2010 and were followed up through 2018. We evaluated all-cause mortality and mortality due to cardiovascular disease (CVD), cancer, respiratory and digestive disease. HRs and 95% CIs for all-cause and cause-specific mortality were calculated using Cox proportional hazards models with adjustment for potential confounding variables. Results At baseline, 19.1% of the participants reported regular use of glucosamine supplements. During a median follow-up of 8.9 years (IQR 8.3-9.7 years), 19 882 all-cause deaths were recorded, including 3802 CVD deaths, 8090 cancer deaths, 3380 respiratory disease deaths and 1061 digestive disease deaths. In multivariable adjusted analyses, the HRs associated with glucosamine use were 0.85 (95% CI 0.82 to 0.89) for all-cause mortality, 0.82 (95% CI 0.74 to 0.90) for CVD mortality, 0.94 (95% CI 0.88 to 0.99) for cancer mortality, 0.73 (95% CI 0.66 to 0.81) for respiratory mortality and 0.74 (95% CI 0.62 to 0.90) for digestive mortality. The inverse associations of glucosamine use with all-cause mortality seemed to be somewhat stronger among current than non-current smokers (p for interaction=0.00080). Conclusions Regular glucosamine supplementation was associated with lower mortality due to all causes, cancer, CVD, respiratory and digestive diseases.
UR - http://www.scopus.com/inward/record.url?scp=85083455459&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083455459&partnerID=8YFLogxK
U2 - 10.1136/annrheumdis-2020-217176
DO - 10.1136/annrheumdis-2020-217176
M3 - Article
C2 - 32253185
AN - SCOPUS:85083455459
VL - 79
SP - 829
EP - 836
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
SN - 0003-4967
IS - 6
ER -
